Heart failure has reached epidemic proportions in the United States, affecting an estimated 6.5 million patients in 2014* at a cost of $30.7B annually—projected to reach $69.7B in 2030.
To make matters worse, heart failure patients can also suffer from co-morbidities such as sleep disorder breathing (SDB), leading to poor outcomes as their heart failure symptoms and conditions deteriorate.
In fact, 74% of heart failure patients experience Central Sleep Apnea (CSA), Obstructive Sleep Apnea (OSA), or both—which can significantly worsen heart failure conditions.
Using phrenic nerve/diaphragm stimulation, we’re working to make better outcomes possible for heart failure patients experiencing the negative effects of CSA and OSA. With just one device, the RMx solution can treat two comorbidities in a single patient by minimizing hypoxia and arousals to reduce stress on the heart.
And, we own a substantial IP portfolio of phrenic nerve and diaphragm stimulation patents and published human clinical evidence demonstrating treatment safety and efficacy.
Our goal? To develop a fully-featured product promoting improved clinical outcomes at a lower procedure cost.
Connect with us for more information about the RMx solution.
San Francisco, CA 94107 | 415-297-8547
*Source: Heart Disease and Stroke Statistics–2018 Update
© 2019 RMx, LLC. All Rights Reserved.
CAUTION: Not available for commercial use. Not FDA approved.